{"prompt": "['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', '2.', 'STUDY OBJECTIVES AND ENDPOINTS', 'Table 1:', 'Study Objectives', 'Primary Objective', 'The primary objective of the study is to assess the impact of apremilast 30 mg twice daily (BID),', 'compared to placebo, on health-related quality of life (qol) in subjects with manifestations of plaque', 'psoriasis and impaired quality of life at Week 16.', 'Secondary Objective(s)', 'The secondary objectives are:', 'To assess the efficacy and safety of apremilast 30 mg BID, compared to placebo in subjects with', 'manifestations of plaque psoriasis and impaired quality of life at Week 16', 'To assess the long-term effects of apremilast 30 mg BID, with respect to quality of life, efficacy, and', 'safety at Weeks 32 and 52', 'Exploratory Objective(s)', 'The exploratory objectives are:', 'To assess the efficacy of apremilast 30 mg BID, compared to placebo in subgroups of subjects with', 'specific manifestations', 'Table 2:', 'Study Enppoints', 'Endpoint', 'Name', 'Description', 'Timeframe', 'Primary', 'Dermatology Life Quality', 'Proportion of subjects who achieve', 'Weeks 16', 'Index (DLQI)', 'a > 4-point reduction from baseline', 'Secondary', 'DLQI', 'Proportion of subjects who achieve', 'Weeks 32, 52', 'a > 4-point reduction from baseline', 'DLQI', 'Mean change from baseline', 'Weeks 16, 32, 52', 'Itch Numeric Rating Scale', 'Mean change from baseline in Itch', 'Weeks 16,32,52', '(NRS)', 'NRS score', 'Skin Discomfort/Pain Visual', 'Mean change from baseline in skin', 'Weeks 16,32,52', 'Analog Scale (VAS)', 'discomfort/pain VAS', 'Body Surface Area (BSA)', 'Mean percent change in BSA', 'Weeks 16,32,52', 'affected by psoriasis', 'Patient Benefit Index (PBI)', 'Proportion of subjects who achieve', 'Weeks 16,32,52', 'PBI score of >', '1', 'Psoriasis Area Severity Index', 'Proportion of subjects who achieve', 'Weeks 16,32,52', '(PASI)', 'PASI < 3', 'Confidential and Proprietary', '20', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', 'Table 2:', 'Study Enppoints (Continued)', 'Endpoint', 'Name', 'Description', 'Timeframe', 'European Quality of Life 5-', 'Mean percent change from', 'Weeks 16, 52', 'Dimension (EQ-5D)', 'baseline in EQ-5D score', 'Work Productivity and', 'Mean change in WPAI domain', 'Weeks 16, 52', 'Activity Impairment', 'scores', 'Questionnaire: Psoriasis', '(WPAI: PSO)', 'Treatment-emergent Adverse', 'Frequency and incidence rate of', 'During double-', 'events', 'any TEAE by SOC, PT, severity,', 'blinded treatment', 'and relationship of adverse events', 'and throughout the', '(AEs) to investigational product', 'duration of the', '(IP).', 'apremilast treatment', 'Clinically significant changes', 'Frequency of clinically', 'During double-', 'in body weight, waist', 'significant changes in body', 'blinded treatment', 'circumference, vital signs,', 'weight, waist circumference, vital', 'and throughout the', 'and/or laboratory findings', 'signs, and/or laboratory findings.', 'duration of the', 'apremilast treatment', 'Exploratory', 'Static Physician Global', 'Proportion of subjects who', 'Weeks 16, 32, 52', 'Assessment (sPGA) of', 'achieve sPGA score of 0 or 1', 'Visible locations', '(among subjects randomized with', 'moderate to severe psoriasis in', 'visible areas, defined as sPGA >', '3, which include the dorsal hand,', 'face, neck, or hairline)', 'Scalp Physician Global', 'Proportion of subjects who', 'Weeks 16, 32, 52', 'Assessment (ScPGA)', 'achieve ScPGA score of 0 or 1', '(among subjects randomized with', 'moderate to severe scalp', 'psoriasis, ScPGA > 3)', 'Nail Psoriasis Severity Index', 'Proportion of subjects who', 'Weeks 16, 32, 52', '(NAPSI)', 'achieve NAPSI score of 0 in the', 'target fingernail (among subjects', 'randomized with presence of nail', 'psoriasis, defined as onycholysis', 'and onychodystrophy in at least 2', 'fingernails)', 'Confidential and Proprietary', '21', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']\n\n###\n\n", "completion": "END"}